Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
BETHESDA, Md., May 17, 2013 (GLOBE NEWSWIRE) -- AREVA Med, an AREVA subsidiary specializing in the development of new innovative therapies to fight cancer, announced today that it will present pharmacokinetics data on the company’s ongoing Phase 1 clinical trial of its alpha radioimmunotherapy 212Pb-TCMC-Trastuzumab in patients with intra-abdominal cancers. The data will be presented at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting in Vancouver, June 8-12, 2013.
Help employers find you! Check out all the jobs and post your resume.
